..

Volumen 10, Asunto 8 (2021)

Editorial

Editorial - Announcement

Fizal

The Journal of Integrative Oncology is a leading research journal dedicated to promote inspiring research outcome to the biological community. This leading-edge, open access journal encompasses diverse fields such as: Clinical and Healthcare Research, Immunology, Stem Cell Research, Genetics, and Medicine in addition to integrative oncology related topics associated with the cancer research. The Journal compiles the latest oncology associated research thereby provides its readers an edge over the others.

Comunicación corta

Genomics versus metabolomics in disease diagnosis

Subrahmanyam Vangala

Aim: To study the genomics versus metabolomics in disease diagnosis. This study focuses on metabolomics in disease diagnosis and how a combined genotype-phenotype approach can help in accurate disease diagnosis, especially in the early stages of disease.

Comunicación corta

Secondary Breast Cancer Diagnosis May 2015 to the Spine And Sacrum

Ruth Urquhart

I was first diagnosed with this disease when I was 37 and had hoped that as the 10 year landmark came and went that I was not going to revisit this disease. I was wrong, at the age of 51 I suffered excruciating pain to my spine and was told that my cancer had returned and was now incurable. Previous visits to my GP with my deteriorating back condition had not considered a recurrence of my disease instead the GP thought I was suffering from acute muscle spasms

Comunicación corta

Transition Metal Complexes/Organometallic Compounds as Anticancer/Anti HIV Drugs Or in Pharmaceutical Industry

Prakash Kinthada

Cancer is a dreadful disease and any practical solution in combating this disease is of paramount importance to public health. Cancer patients have burdened by drug induced toxic side effects, and no turned to seek help from the complementary and alternative medicine hoping for a better cure. Research on Platinum based drugs and Non-Platinum based drugs is a Multi-Million Dollar Industry in USA and there is every need to produce safe drugs for the cure of this monstrous disease. Flavonoids have a long history of use in traditional medicines in many cultures. The phytochemical, curcumin is one of the major dietary flavonoids, belonging to a group of flavonol, Curcumin is a natural polyphenol. It is highly potential molecule capable of preventing and treating various cancers. Various dietary chemo preventive agents, turmeric powder or its extract are broadly used as therapeutic preparations in Indian System of medicine.

Comunicación corta

Role of Post Mastectomy Radiotherapy in T1, T2 Lesions With 1-3 Positive Axillary Lymph Nodes Study Of 101 Cases

Nikhil Garg

Background: Post mastectomy radiotherapy (PMRT) reduces loco-regional recurrence (LRR) and improves overall survival.There is international consensus to recommend PMRT for patients with tumour size more than 5 cm, tumour invasion of the skin, pectoral muscle or chest wall and patients with > 4 positive lymph nodes. However, the role of PMRT for patients with T1 , T2 disease with 1â??3 positive LN is still controversial. The side effects of radiotherapy and its associated morbidity have to be considered in the risk benefit ratio, thus difficult to arrive at consensus in early breast cancer. Methods: 101 patients treated between 2012 to 2015 were studied retrospectively, The inclusion criteria for this analysis were:(1) Female patients with unilateral breast cancer and no distant metastasis at initial diagnosis who underwent mastectomy and axillary lymph node dissection; (2) postoperative pathology indicated T1â??2 and 1â??3 positive axillary lymph nodes (T1â??2N1M0) disease, at least 10 lymph nodes removed by axillary dissection; (3) complete surgical resection of the tumor and negative margins; (4) complete estrogen receptor (ER), progesterone receptor (PR) and human epithelial growth factor receptor family 2 (Her2) status; (5) No neoadjuvant chemotherapy was administered before surgery and endocrine therapy was performed based on the hormone receptor status. In order to study the research questions, we formulated hypotheses as follows,1. Radiotherapy does not have any impact on recurrence post mastectomy.2. There is no influence of Peri nodal extension on recurrence. The above hypotheses were tested using chi- square test. Results: Recurrences were obtained in 9 amongst radiotherapy and without radiotherapy in 16.When chi square was applied ,the value was highly significant. Hence our hypothesis was rejected. Also in case of PNE with recurrence and radiotherapy,8 had PNE with radiotherapy and recurrence and 27 had no recurrence, p value was 0.013% hence highly significant. Conclusions: Radiotherapy should be strongly considered in patients with 1-3 nodes post mastectomy as it decreases the chances of recurrence
Artículo de investigación

Visiting Community-Based Psychosocial Support Centers for Cancer Patients and Their Relatives: A Buffer for the Decrease in Health Quality of Life.

Adriaan Visser

Introduction: PIntroduction: Psychosocial treatments may prevent the decrease of the perceived HQoL of cancer patients with a good medical condition. However, contrarily, psychosocial support may not prevent the decrease their HQoL, but only stabilized it, in case of a bad medical condition. The explanatory factor of the effect of psychosocial support may be the severity of the medical condition of patients. This hypothesis was tested in an intervention among Dutch cancer patients visiting a Community Based Support Centre (CBSC), offering contacts with fellow patients, psychological treatment, and participation in supportive activities (e.g. walking, music and art therapy, mindfulness training, cooking courses). Methods: A mixed methods study was held among 20 CBSC’s, including 24 visitors about the meaning of their HQoL. In a digital survey at two timepoints (T-1, a few months after the first visit) and again after 3 months-5 months (T-2), the HQoL was studied using three questions of the standardized EORTC measure, beside validated questions on the medical condition, fatigue, sleeping, pain, short-breathing, and perceived prognosis. All measures are very reliable showed by Cronbach alpha coefficients between 0.72 and 0.96. Results: The studies confirmed that visiting CBSCs enable their well-being and the communication about HQoL. In total 203 visitors responded at both time points, revealing that between T1-T2, the HQoL decreased (p<0.05) from 5.3 to 5.1 (seven-point scale). In multivariate analysis the influence of eight confounding factors was studied to explain this result: Social and medical characteristics, medical condition, morbidities, being an (ex) patient or relative with/without cancer, changes in health, stressful life events, number of visits, and perceived meaning of the visits. Only the severity of the medical condition plaid a role in the decrease of HQoL. For visitors with a better medical condition at T-1 the HQoL decreased, while for visitors with a rather worse medical condition at T1, the HQoL did not change. Conclusion: The results confirm the hypothesis that a psychosocial intervention (visiting CBSCs) decreases the HQoL over 3 months-5 months as part of their adaptation process. However, for visitors with a poorer medical condition, the HQoL remained stable over time. This implies that psychosocial interventions (e.g. visiting a CBSC) are functioning as a buffer against decreasing HQoL for those in a poor medical condition only.

Editorial

A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) Technology Using Natural Tumor Sensitizers for Treatment Of Triple Negative Breast Cancer Patients

Raghu Pandurangi

Statement of the Problem: Cancer cells have inherent ability to circumvent intervention irrespective of the nature of intervention by desensitizing themselves through a) activating survival pathways (e.g. NF-kB, PARP) and downregulating cell death pathways (e.g. CD95, ASK1) simultaneously. The situation is worse for triple negative breast cancer (TNBC) patients who have no option except non-specific chemotherapy, despite high off-target toxicity. No targeted therapy is approved for TNBC treatment since TNBC lack biomarkers (e.g. PR, ER and HER2 negative) for which drugs are designed. This puts TNBC patients on an enormous risk for survival. The purpose of this study is to make FDA approved drugs better using AAAPT technology.

Indexado en

arrow_upward arrow_upward